Browsing Tag
Patrick Vink
2 posts
Avacta Group (AIM: AVCT) company profile: Can pre|CISION make potent cancer drugs safer and more targeted?
Avacta Group plc is developing peptide drug conjugates intended to release potent anticancer payloads primarily within the tumour microenvironment. Early AVA6000 findings and the launch of the AVA6103 trial have strengthened the scientific case, but larger clinical studies, partnership funding and management of the remaining convertible bond will determine whether pre|CISION creates sustainable shareholder value.
Avacta (AIM: AVCT) just paid down £3.67m of bond debt in cash. The real question is what AVA6103 does next.
Avacta cleared bond debt in cash and reaches its AVA6103 readout on funded runway. The next six months decide whether pre|CISION reads as one drug or a platform.